|
|
| Line 27: |
Line 27: |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] | | | colspan="1" style="text-align:center; background:LightGreen"|[[ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] |
| |- | | |- |
| | bgcolor="LightGreen"|<nowiki></nowiki>'''1.''' [[Cardiopulmonary resuscitation|CPR]] should be performed in [[patients]] in [[cardiac arrest]] according to published [[Basic life support|basic]] and [[advanced cardiovascular life support]] algorithms ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''.<ref name="LinkBerkow2015">{{cite journal|last1=Link|first1=Mark S.|last2=Berkow|first2=Lauren C.|last3=Kudenchuk|first3=Peter J.|last4=Halperin|first4=Henry R.|last5=Hess|first5=Erik P.|last6=Moitra|first6=Vivek K.|last7=Neumar|first7=Robert W.|last8=O’Neil|first8=Brian J.|last9=Paxton|first9=James H.|last10=Silvers|first10=Scott M.|last11=White|first11=Roger D.|last12=Yannopoulos|first12=Demetris|last13=Donnino|first13=Michael W.|title=Part 7: Adult Advanced Cardiovascular Life Support|journal=Circulation|volume=132|issue=18 suppl 2|year=2015|pages=S444–S464|issn=0009-7322|doi=10.1161/CIR.0000000000000261}}</ref><ref name="StiellWells2004">{{cite journal|last1=Stiell|first1=Ian G.|last2=Wells|first2=George A.|last3=Field|first3=Brian|last4=Spaite|first4=Daniel W.|last5=Nesbitt|first5=Lisa P.|last6=De Maio|first6=Valerie J.|last7=Nichol|first7=Graham|last8=Cousineau|first8=Donna|last9=Blackburn|first9=Josée|last10=Munkley|first10=Doug|last11=Luinstra-Toohey|first11=Lorraine|last12=Campeau|first12=Tony|last13=Dagnone|first13=Eugene|last14=Lyver|first14=Marion|title=Advanced Cardiac Life Support in Out-of-Hospital Cardiac Arrest|journal=New England Journal of Medicine|volume=351|issue=7|year=2004|pages=647–656|issn=0028-4793|doi=10.1056/NEJMoa040325}}</ref><ref name="SassonRogers2010">{{cite journal|last1=Sasson|first1=Comilla|last2=Rogers|first2=Mary A.M.|last3=Dahl|first3=Jason|last4=Kellermann|first4=Arthur L.|title=Predictors of Survival From Out-of-Hospital Cardiac Arrest|journal=Circulation: Cardiovascular Quality and Outcomes|volume=3|issue=1|year=2010|pages=63–81|issn=1941-7713|doi=10.1161/CIRCOUTCOMES.109.889576}}</ref> | | | bgcolor="LightGreen"|<nowiki></nowiki>'''1.''' In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-R]])'' or stable sustained VT (LOE: B-NR) S7.1.1-5 not due to reversible causes, an ICD is recommended if meaningful survival greater than 1 year is expected. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]])''. |
|
| |
|
| '''2.''' In [[patients]] with [[hemodynamically]] unstable [[Ventricular arrhythmia|VA]] that persist or recur after a maximal energy shock, [[intravenous]] [[amiodarone]] should be administered to attempt to achieve a stable [[rhythm]] after further [[defibrillation]] ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''. <ref name="LinkBerkow2015">{{cite journal|last1=Link|first1=Mark S.|last2=Berkow|first2=Lauren C.|last3=Kudenchuk|first3=Peter J.|last4=Halperin|first4=Henry R.|last5=Hess|first5=Erik P.|last6=Moitra|first6=Vivek K.|last7=Neumar|first7=Robert W.|last8=O’Neil|first8=Brian J.|last9=Paxton|first9=James H.|last10=Silvers|first10=Scott M.|last11=White|first11=Roger D.|last12=Yannopoulos|first12=Demetris|last13=Donnino|first13=Michael W.|title=Part 7: Adult Advanced Cardiovascular Life Support|journal=Circulation|volume=132|issue=18 suppl 2|year=2015|pages=S444–S464|issn=0009-7322|doi=10.1161/CIR.0000000000000261}}</ref><ref name="DorianCass2002">{{cite journal|last1=Dorian|first1=Paul|last2=Cass|first2=Dan|last3=Schwartz|first3=Brian|last4=Cooper|first4=Richard|last5=Gelaznikas|first5=Robert|last6=Barr|first6=Aiala|title=Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular Fibrillation|journal=New England Journal of Medicine|volume=346|issue=12|year=2002|pages=884–890|issn=0028-4793|doi=10.1056/NEJMoa013029}}</ref><ref>{{Cite journal | | '''2.''' A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient’s risk of death due to a VA is deemed high and the risk |
| | author = [[P. J. Kudenchuk]], [[L. A. Cobb]], [[M. K. Copass]], [[R. O. Cummins]], [[A. M. Doherty]], [[C. E. Fahrenbruch]], [[A. P. Hallstrom]], [[W. A. Murray]], [[M. Olsufka]] & [[T. Walsh]]
| | of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient’s burden of comorbidities and functional status ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-R]])''. |
| | title = Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
| |
| | journal = [[The New England journal of medicine]]
| |
| | volume = 341
| |
| | issue = 12
| |
| | pages = 871–878
| |
| | year = 1999
| |
| | month = September
| |
| | doi = 10.1056/NEJM199909163411203
| |
| | pmid = 10486418
| |
| }}</ref>
| |
|
| |
|
| '''3.''' [[Patients]] presenting with [[Ventricular arrhythmia|VA]] with [[hemodynamic]] instability should undergo direct current [[cardioversion]] ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''.<ref name="LinkBerkow2015">{{cite journal|last1=Link|first1=Mark S.|last2=Berkow|first2=Lauren C.|last3=Kudenchuk|first3=Peter J.|last4=Halperin|first4=Henry R.|last5=Hess|first5=Erik P.|last6=Moitra|first6=Vivek K.|last7=Neumar|first7=Robert W.|last8=O’Neil|first8=Brian J.|last9=Paxton|first9=James H.|last10=Silvers|first10=Scott M.|last11=White|first11=Roger D.|last12=Yannopoulos|first12=Demetris|last13=Donnino|first13=Michael W.|title=Part 7: Adult Advanced Cardiovascular Life Support|journal=Circulation|volume=132|issue=18 suppl 2|year=2015|pages=S444–S464|issn=0009-7322|doi=10.1161/CIR.0000000000000261}}</ref><ref name="StiellWells2004">{{cite journal|last1=Stiell|first1=Ian G.|last2=Wells|first2=George A.|last3=Field|first3=Brian|last4=Spaite|first4=Daniel W.|last5=Nesbitt|first5=Lisa P.|last6=De Maio|first6=Valerie J.|last7=Nichol|first7=Graham|last8=Cousineau|first8=Donna|last9=Blackburn|first9=Josée|last10=Munkley|first10=Doug|last11=Luinstra-Toohey|first11=Lorraine|last12=Campeau|first12=Tony|last13=Dagnone|first13=Eugene|last14=Lyver|first14=Marion|title=Advanced Cardiac Life Support in Out-of-Hospital Cardiac Arrest|journal=New England Journal of Medicine|volume=351|issue=7|year=2004|pages=647–656|issn=0028-4793|doi=10.1056/NEJMoa040325}}</ref><ref name="SassonRogers2010">{{cite journal|last1=Sasson|first1=Comilla|last2=Rogers|first2=Mary A.M.|last3=Dahl|first3=Jason|last4=Kellermann|first4=Arthur L.|title=Predictors of Survival From Out-of-Hospital Cardiac Arrest|journal=Circulation: Cardiovascular Quality and Outcomes|volume=3|issue=1|year=2010|pages=63–81|issn=1941-7713|doi=10.1161/CIRCOUTCOMES.109.889576}}</ref>''<nowiki/>'' | | '''3.''' In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]])''.''<nowiki/>'' |
|
| |
|
|
| |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]
Recommendations for Secondary Prevention of SCD in Patients With Ischemic Heart Disease
| Class I
|
| 1. In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT (Level of Evidence: B-R) or stable sustained VT (LOE: B-NR) S7.1.1-5 not due to reversible causes, an ICD is recommended if meaningful survival greater than 1 year is expected. (Level of Evidence: B-NR).
2. A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient’s risk of death due to a VA is deemed high and the risk
of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient’s burden of comorbidities and functional status (Level of Evidence: B-R).
3. In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected (Level of Evidence: B-NR).
|
References
Template:WH
Template:WS